Study guide

10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders

AACN Cardiac Medicine Certification CMC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview and the CMC Test Plan

1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them

2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease

2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy

3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease

3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup

4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions

4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation

5 Chapter 5: Vascular Conditions and Vascular Interventions

5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications

6 Chapter 6: Shock States and Mechanical Circulatory Support

6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD

7 Chapter 7: Cardiac Procedures and Structural Heart Interventions

7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications

8 Chapter 8: Cardiovascular Pharmacology

8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure

9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary

9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients

10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral

10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients

11 Chapter 11: Monitoring and Diagnostics

11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography

12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions

12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease

10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders

Key Takeaways Explain This Topic AI

HIT is a prothrombotic state: platelets fall more than 50% on days 5-10 of heparin exposure (or within 24 hours if exposed in the prior 100 days), with a 30-50% thrombosis rate and a 5-10% per day risk if untreated.

The 4Ts score bands are 0-3 low, 4-5 intermediate, and 6-8 high probability; a low score has a negative predictive value near 99% and should stop the workup.

In HIT: stop all heparin including flushes and coated devices, start a therapeutic non-heparin anticoagulant such as argatroban 2 mcg/kg/min (0.5-1.2 in hepatic dysfunction or heart failure) titrated to aPTT 1.5-3 times baseline, avoid platelet transfusion, and withhold warfarin until platelets recover to 150 x 10^9/L or more.

DIC treatment is source control plus targeted replacement for bleeding - platelets below 50 with bleeding, plasma when PT/aPTT exceeds 1.5 times normal, cryoprecipitate for fibrinogen below 150 mg/dL - not reflexive correction of numbers.

In Heyde syndrome and continuous-flow LVAD patients, acquired von Willebrand syndrome causes bleeding with a completely normal platelet count, PT, aPTT and INR; valve replacement corrects the aortic stenosis form.

Last updated: August 2026

Heparin-Induced Thrombocytopenia: the Highest-Yield Coagulopathy in Cardiac Care

Nearly every patient in a cardiac unit is exposed to heparin — therapeutic infusions for ACS, prophylactic subcutaneous doses, line flushes, heparin-bonded pulmonary artery catheters and intra-aortic balloon pumps, cardiopulmonary bypass, and dialysis circuits. Heparin-induced thrombocytopenia (HIT) is therefore a CMC exam staple.

Distinguish the two types immediately. Type 1 is a non-immune, direct platelet-aggregating effect: a mild fall within the first 1 to 2 days, a nadir rarely below 100 x 10^9/L, spontaneous recovery even with continued heparin, and no thrombotic risk. Type 2 is the immune, prothrombotic syndrome that everything below describes.

Pathophysiology and timing

Heparin binds platelet factor 4 (PF4) , a positively charged protein released from platelet alpha granules. The heparin-PF4 complex is immunogenic; IgG antibodies form against it, and the resulting immune complexes cross-link FcgammaRIIa receptors on platelets, activating them. Activated platelets aggregate, are cleared by the spleen (hence the thrombocytopenia), and shed procoagulant microparticles. The antibodies also activate monocytes and endothelium, driving tissue factor expression and explosive thrombin generation. HIT is a hypercoagulable state that happens to lower the platelet count — that paradox is the whole clinical point.

Incidence is roughly 0.2 to 5 percent, higher with unfractionated than low-molecular-weight heparin, higher in surgical than medical patients, and highest after cardiac surgery, where up to half of patients develop antibodies but only 1 to 3 percent develop clinical HIT.

The timing rules:

Typical onset: platelet count falls by more than 50 percent from baseline on days 5 to 10 of heparin exposure. The nadir is usually 50 to 70 x 10^9/L; a count below 20 x 10^9/L argues against HIT.

Rapid onset: the fall occurs within 24 hours of re-exposure in a patient who received heparin within the preceding 100 days and still has circulating antibodies.

Delayed-onset HIT: thrombocytopenia and thrombosis begin days to weeks after heparin has already been stopped, sometimes after discharge.

Note the cardiac-surgery confounder: platelets normally fall after cardiopulmonary bypass and recover by postoperative day 3 to 4. A secondary fall after day 5 , or a failure to recover, is the suspicious pattern.

The 4Ts score

Category 2 points 1 point 0 points

T hrombocytopenia Fall greater than 50% AND nadir 20 x 10^9/L or above Fall of 30-50%, OR nadir 10-19 x 10^9/L Fall less than 30%, OR nadir below 10 x 10^9/L

T iming of fall Clear onset days 5-10, or fall within 1 day with heparin exposure in the past 30 days Consistent with days 5-10 but unclear, onset after day 10, or fall within 1 day with exposure 30-100 days ago Fall at less than 4 days with no recent exposure

T hrombosis or other sequelae New confirmed thrombosis, skin necrosis at an injection site, or acute systemic reaction after an IV heparin bolus Progressive or recurrent thrombosis, non-necrotizing erythematous skin lesions, suspected but unproven thrombosis None

o T her cause of thrombocytopenia None apparent Possible Definite

Interpretation: 0 to 3 = low probability (negative predictive value near 99 percent), 4 to 5 = intermediate, 6 to 8 = high probability. A low 4Ts score essentially excludes HIT and should stop the workup — testing low-probability patients generates false positives that lead to unnecessary and expensive alternative anticoagulation.

Testing

The PF4 immunoassay (ELISA) is sensitive (above 95 percent) but poorly specific; many patients have antibodies without clinical disease. The magnitude matters — an optical density above 2.0 substantially raises the likelihood of true HIT. The confirmatory functional test is the serotonin release assay (SRA) , the gold standard, with high specificity but a send-out turnaround of days. You do not wait for it: treat on clinical probability and adjust.

Management rules

Stop ALL heparin. That means the infusion, subcutaneous prophylaxis, line flushes , heparin-bonded catheters and intra-aortic balloon pump sheaths, heparin in the dialysis or CRRT circuit, and heparin-containing total parenteral nutrition. Flag the chart and the wristband. Missing the flushes is a recurring exam trap and a real-world one.

Start a therapeutic-dose non-heparin anticoagulant immediately , even with isolated HIT and no clot. Untreated HIT carries a 5 to 10 percent per day risk of new thrombosis and a 30 to 50 percent overall thrombosis rate. "Stop the heparin and watch the platelets" is wrong.

Argatroban — direct thrombin inhibitor, hepatically cleared , half-life 40 to 50 minutes. Start at 2 mcg/kg/min, but reduce to 0.5 to 1.2 mcg/kg/min in hepatic dysfunction, heart failure, anasarca, post-cardiac-surgery and multi-organ failure . Titrate to an aPTT 1.5 to 3 times baseline and generally not above 100 seconds. It artificially prolongs the INR, which complicates warfarin transition.

Bivalirudin — direct thrombin inhibitor, largely enzymatic clearance with about 20 percent renal, half-life 25 minutes; the usual choice when a HIT patient needs PCI or cardiac surgery.

Fondaparinux — indirect factor Xa inhibitor, once-daily subcutaneous, renally cleared; avoid with creatinine clearance below 30 mL/min.

Direct oral anticoagulants (rivaroxaban, apixaban) are acceptable for clinically stable patients per current hematology guidance.

Do not give prophylactic platelet transfusions. Adding platelets to a prothrombotic state has been associated with arterial thrombosis and death. Reserve transfusion for active clinically significant bleeding.

Do not start or continue warfarin until the platelet count has recovered to 150 x 10^9/L or above and the patient is therapeutically anticoagulated on a non-heparin agent. Warfarin depletes protein C faster than the vitamin K-dependent procoagulant factors, and in the thrombin-saturated state of HIT this precipitates venous limb gangrene and warfarin-induced skin necrosis . If warfarin was already given, reverse it with vitamin K 5 to 10 mg IV.

Overlap warfarin with the parenteral agent for at least 5 days and until the INR is therapeutic. With argatroban, use a chromogenic factor X level or repeat the INR 2 hours after stopping the infusion.

Duration: 3 months with thrombosis; at least 4 weeks (through platelet recovery) with isolated HIT.

Nursing surveillance: trend the platelet count at least every other day in any patient receiving heparin for more than 4 days, compare against the admission baseline rather than the previous day, assess limbs for new pain, pallor, pulselessness or discoloration, watch injection sites for necrotic lesions, and educate the patient that heparin avoidance is lifelong and must be reported at every future admission.

Loading diagram... Suspected HIT: 4Ts-driven workflow

Disseminated Intravascular Coagulation

Disseminated intravascular coagulation (DIC) is systemic activation of coagulation with microvascular fibrin deposition, consumption of platelets and clotting factors, and secondary fibrinolysis. It is always a complication of something else , and the triggers relevant to cardiac care are sepsis and septic shock, prolonged cardiac arrest with ischemia-reperfusion injury, massive transfusion and trauma, extracorporeal membrane oxygenation and ventricular assist device circuits, malignancy, acute promyelocytic leukemia, hemolytic transfusion reaction, and obstetric catastrophe.

Two phenotypes matter clinically: a thrombotic (organ-failure) phenotype typical of sepsis, with microvascular thrombosis, acral ischemia, and purpura fulminans; and a fibrinolytic (bleeding) phenotype typical of acute promyelocytic leukemia, trauma, and aortic aneurysm.

The laboratory pattern:

  • Falling platelet count — the trend is more informative than any single value
  • Prolonged PT/INR , then prolonged aPTT

Low fibrinogen , typically below 100 to 150 mg/dL. Beware: fibrinogen is an acute-phase reactant that rises in sepsis and after surgery, so a "normal" 200 mg/dL in a septic patient may represent a large relative fall.

  • Markedly elevated D-dimer and fibrin degradation products
  • Schistocytes on the peripheral smear, falling antithrombin, and falling protein C

The ISTH overt-DIC score operationalizes this: platelet count (above 100 = 0, below 100 = 1, below 50 = 2), D-dimer or fibrin marker (no rise = 0, moderate = 2, strong = 3), PT prolongation (under 3 seconds = 0, 3 to 6 seconds = 1, over 6 seconds = 2), and fibrinogen (above 100 mg/dL = 0, below 100 = 1). A score of 5 or more is compatible with overt DIC ; repeat daily, because the trajectory carries the information.

Treatment principle — the one the exam tests: the treatment for DIC is treating the cause . Source control of sepsis, delivery of the fetus, restoring perfusion, treating the leukemia. Blood products are given for bleeding or a planned invasive procedure , not to normalize a number on a screen:

Platelets if below 50 x 10^9/L with bleeding or before a procedure (below 10 to 20 x 10^9/L for prophylaxis in the non-bleeding patient)

Fresh frozen plasma 15 to 20 mL/kg if the PT or aPTT exceeds 1.5 times normal with bleeding

Cryoprecipitate or fibrinogen concentrate if fibrinogen is below 150 mg/dL with bleeding; roughly 10 units of cryoprecipitate raise fibrinogen by 50 to 100 mg/dL

Therapeutic heparin only in the predominantly thrombotic phenotype — purpura fulminans, digital ischemia, large-vessel thrombosis

Avoid antifibrinolytics such as tranexamic acid in classic DIC; blocking fibrinolysis in a patient depositing microvascular fibrin worsens organ failure. Hyperfibrinolytic variants are a specialist exception.

Differentials worth holding in mind: thrombotic thrombocytopenic purpura (severe thrombocytopenia and hemolysis with a normal PT and fibrinogen, ADAMTS13 activity below 10 percent), HIT (normal PT and fibrinogen, higher platelet nadir), liver disease (factor VIII is normal or high in liver failure but low in DIC , which is the classic discriminator), and HELLP syndrome.

  • Other Coagulopathies the Cardiac Nurse Must Recognize
  • Acquired von Willebrand syndrome

High shear stress unfolds von Willebrand factor and exposes it to cleavage by ADAMTS13, stripping out the high-molecular-weight multimers that mediate platelet adhesion. Two cardiac settings produce exactly this:

Severe aortic stenosis. Combined with the gastrointestinal angiodysplasia that low pulse pressure and hypoxia promote, this is Heyde syndrome — the triad of severe aortic stenosis, acquired von Willebrand syndrome, and recurrent GI bleeding from angiodysplasia. Aortic valve replacement, surgical or transcatheter, corrects the coagulopathy and usually stops the bleeding.

Continuous-flow left ventricular assist devices. GI bleeding is the leading cause of readmission in LVAD recipients, driven by the same multimer loss plus reduced pulsatility and angiodysplasia. Management includes reducing INR targets and holding aspirin, octreotide, endoscopic therapy, and in refractory cases increasing pulsatility.

The trap: in acquired von Willebrand syndrome the platelet count, PT, aPTT, and INR are all normal . A normal coagulation screen does not exclude a bleeding disorder. Diagnosis requires von Willebrand multimer analysis, a low von Willebrand factor collagen-binding-to-antigen ratio, or platelet function analyzer testing.

Post-cardiac-surgery and dilutional coagulopathy

After cardiopulmonary bypass, bleeding is usually multifactorial: hemodilution of factors and platelets, hypothermia (enzyme kinetics and platelet function are impaired below about 35 degrees Celsius — rewarm before concluding the patient has a factor deficiency), acidosis (pH below 7.1 markedly impairs thrombin generation), bypass-induced platelet dysfunction, residual or rebound heparin, hyperfibrinolysis, and surgical bleeding. Check the activated clotting time and consider additional protamine for residual heparin; the "lethal triad" of hypothermia, acidosis, and coagulopathy must be corrected in parallel, not sequentially.

Drug-related bleeding and reversal

Agent Reversal / management

Unfractionated heparin Protamine 1 mg per 100 units of heparin given in the previous 2-3 hours; watch for hypotension, bradycardia, and anaphylactoid reaction with rapid infusion

Low-molecular-weight heparin Protamine is only partially effective, roughly 60%

Warfarin 4-factor prothrombin complex concentrate 25-50 units/kg plus vitamin K 10 mg IV; plasma only if PCC is unavailable

  • Dabigatran Idarucizumab 5 g IV
  • Apixaban / rivaroxaban Andexanet alfa, or 4-factor PCC where andexanet is unavailable

Aspirin / P2Y12 inhibitors Platelet transfusion has limited benefit and was harmful in intracerebral hemorrhage on antiplatelet therapy; desmopressin 0.3 mcg/kg IV helps uremic and aspirin-related platelet dysfunction

Device- and disease-related thrombocytopenia

Intra-aortic balloon pumps cause mechanical platelet destruction, usually a modest fall that recovers after removal. ECMO produces consumption, shear-mediated platelet dysfunction, and acquired von Willebrand syndrome simultaneously. Continuous renal replacement therapy circuits consume platelets and fibrinogen. Liver disease produces a rebalanced hemostatic state in which both procoagulants and anticoagulants fall — the INR in cirrhosis does not predict bleeding and should not be "corrected" reflexively before procedures.

Product thresholds and viscoelastic testing

Product Usual threshold

Platelets Below 10 x 10^9/L prophylactic in a stable patient; below 20 with fever or sepsis; below 50 for an invasive procedure or active bleeding; below 100 for neurosurgery, intracranial bleeding, or microvascular bleeding after bypass

  • Fresh frozen plasma INR above 1.5-2.0 with bleeding or before an urgent procedure; 10-15 mL/kg
  • Cryoprecipitate Fibrinogen below 150-200 mg/dL with bleeding

Viscoelastic testing (thromboelastography, TEG, or rotational thromboelastometry, ROTEM) shows the whole clot in real time and directs targeted therapy rather than shotgun transfusion:

Prolonged R time / CT = factor deficiency, treat with plasma or PCC

Prolonged K time , reduced alpha angle / CFT = fibrinogen deficiency, treat with cryoprecipitate or fibrinogen concentrate

Reduced maximum amplitude (MA) / MCF = platelet number or function problem, treat with platelets, and consider desmopressin

Elevated LY30 / ML = hyperfibrinolysis, treat with an antifibrinolytic

A heparinase-treated channel that normalizes identifies residual heparin , which is treated with protamine, not plasma

Algorithm-guided viscoelastic management reduces transfusion in cardiac surgery and is recommended in patient blood management guidance.

Nursing bleeding surveillance

Trend hemoglobin and platelets against the admission baseline, not the last value. Quantify chest tube drainage hourly — more than 200 mL/hr for 2 consecutive hours or more than 300 mL in any single hour warrants surgical notification , and an abrupt cessation of previously brisk drainage with rising filling pressures, narrowing pulse pressure, and equalizing diastolic pressures signals tamponade , not improvement. After femoral arterial access, unexplained hypotension with flank or back pain and a falling hemoglobin without an obvious external source is retroperitoneal hemorrhage until imaging says otherwise. Add routine stool guaiac in anticoagulated patients, serial neurologic checks, site and dressing checks each shift, minimized venipuncture and arterial punctures, soft toothbrushes and electric razors, no intramuscular injections, and proton pump inhibitor prophylaxis for patients on dual antiplatelet therapy with additional risk factors.